Lexaria Bioscience Management
Management criteria checks 2/4
Lexaria Bioscience's CEO is Rich Christopher, appointed in Aug 2024, has a tenure of less than a year. directly owns 0.29% of the company’s shares, worth $115.00K. The average tenure of the management team and the board of directors is 0.3 years and 4 years respectively.
Key information
Rich Christopher
Chief executive officer
US$519.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO
Rich Christopher (54 yo)
less than a year
Tenure
US$519,317
Compensation
Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024. He served as Chief Financial Officer and Treasurer of InVivo Therapeutics Holdin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | US$519.32k | 0.29% $ 115.0k | |
| Chairman of the Scientific Advisory Board | 9.8yrs | US$414.42k | 0% $ 0 | |
| Chief Financial Officer | less than a year | no data | no data | |
| Director of Operations | no data | no data | no data | |
| Head of Legal | no data | no data | 0% $ 0 | |
| Chief Medical Advisor & Member of Scientific Advisory Board | less than a year | no data | no data |
0.3yrs
Average Tenure
55yo
Average Age
Experienced Management: LEXX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Scientific Advisory Board | 8.8yrs | US$414.42k | 0% $ 0 | |
| Chief Medical Advisor & Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 4yrs | US$74.83k | 0.063% $ 25.1k | |
| Chairman of the Board | 18.3yrs | US$884.84k | 1.57% $ 629.1k | |
| Independent Director | 13.5yrs | US$74.83k | 0.063% $ 25.3k | |
| Independent Director | 9.3yrs | US$69.83k | 0.076% $ 30.3k | |
| Independent Director | 2.3yrs | US$74.83k | 0.018% $ 7.1k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
4.0yrs
Average Tenure
66.5yo
Average Age
Experienced Board: LEXX's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 00:19 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lexaria Bioscience Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ammar Shah | Eight Capital |
| Yi Chen | H.C. Wainwright & Co. |
| Michael Okunewitch | Maxim Group |